GlassScriptPhysician profile
Philip J Mcgee
NPI 1265412829
$3,232.91
in general payments reported to CMS, 2019-2025
40 companies · $439 in 2025
The $439 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $118 · 2021: $494 · 2022: $547 · 2023: $335 · 2024: $1,019 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173 · Grant: $501 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.66 |
| Grant | $500.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.50 | 2024 | |
| Welch Allyn | $432.31 | 2021 | |
| Pfizer INC. | $272.76 | 2019-2025 | |
| Seagen INC. | $221.73 | 2020-2023 | Tukysa, Padcev |
| Novartis Pharmaceuticals Corporation | $175.16 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $162.56 | 2019-2025 | Keytruda, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $125.97 | 2021-2025 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $102.67 | 2021-2023 | Epkinly, Imbruvica |
| Daiichi Sankyo INC. | $85.98 | 2020-2025 | Enhertu |
| Genzyme Corporation | $83.90 | 2019-2023 | |
| Janssen Biotech, INC. | $79.71 | 2022-2024 | Tecvayli, Talvey, Darzalex |
| Celgene Corporation | $77.19 | 2022-2024 | Opdualag, Reblozyl |
| Array Biopharma INC | $75.79 | 2019-2025 | Mektovi, Braftovi, Tukysa |
| Springworks Therapeutics, INC. | $70.90 | 2024-2025 | Ogsiveo |
| Amgen INC. | $67.23 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.